Silverarc Capital Management, LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Silverarc Capital Management, LLC disclosed 65 US equity positions worth $898.5m in its Q2 2026 13F filing. The largest position was ASND at 6.1% of the reported book, followed by CELC and COGT. Against the Q1 2026 filing, it opened 14 new positions, added to 14 and reduced 21 among the top 50 holdings.
What did Silverarc Capital Management, LLC own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 6.1% | $55.0m | 206,234 | – | new |
| 2 | CELC CELCUITY INC | Healthcare | 5.8% | $52.4m | 500,996 | 40% | added |
| 3 | COGT COGENT BIOSCIENCES INC | Healthcare | 5.5% | $49.6m | 1,280,707 | -3% | reduced |
| 4 | URGN UROGEN PHARMA LTD | Healthcare | 5.3% | $47.9m | 1,301,979 | -13% | reduced |
| 5 | IMNM IMMUNOME INC | Healthcare | 4.8% | $42.7m | 2,017,009 | 9% | added |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 4.2% | $38.0m | 390,000 | -40% | reduced |
| 7 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.8% | $34.6m | 311,461 | 2% | added |
| 8 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 3.7% | $33.6m | 352,802 | 134% | added |
| 9 | GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 3.0% | $26.8m | 1,108,295 | -45% | reduced |
| 10 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.0% | $26.5m | 1,214,390 | 37% | added |
| 11 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 2.8% | $24.8m | 489,382 | – | new |
| 12 | IMVT IMMUNOVANT INC | Healthcare | 2.7% | $23.9m | 619,096 | 49% | added |
| 13 | ERAS ERASCA INC | Healthcare | 2.6% | $23.1m | 1,263,026 | -32% | reduced |
| 14 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 2.5% | $22.6m | 2,927,698 | – | new |
| 15 | ABVX ABIVAX SA | Healthcare | 2.5% | $22.6m | 169,593 | -44% | reduced |
| 16 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 2.4% | $22.0m | 65,679 | -8% | reduced |
| 17 | KOD KODIAK SCIENCES INC | Healthcare | 2.4% | $21.3m | 546,256 | -45% | reduced |
| 18 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 2.1% | $18.8m | 400,000 | – | new |
| 19 | VCYT VERACYTE INC | Healthcare | 2.1% | $18.7m | 318,001 | 77% | added |
| 20 | GH GUARDANT HEALTH INC | Healthcare | 1.7% | $15.0m | 99,826 | 1% | added |
| 21 | CCCC C4 THERAPEUTICS INC | Healthcare | 1.6% | $14.2m | 3,032,060 | 59% | added |
| 22 | ZBIO ZENAS BIOPHARMA INC | 1.4% | $12.9m | 509,789 | -55% | reduced | |
| 23 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.4% | $12.6m | 678,095 | 33% | added |
| 24 | HELIX ACQUISITION CORP III | 1.4% | $12.5m | 1,177,821 | -3% | reduced | |
| 25 | ALXO ALX ONCOLOGY HLDGS INC | Healthcare | 1.3% | $11.9m | 5,744,757 | – | new |
| 26 | MANE VERADERMICS INC | Healthcare | 1.3% | $11.7m | 95,000 | – | new |
| 27 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.3% | $11.3m | 186,821 | -6% | reduced |
| 28 | AVALYN PHARMACEUTICALS INC | 1.2% | $10.9m | 330,487 | – | new | |
| 29 | BIIB BIOGEN INC | Healthcare | 1.2% | $10.4m | 48,101 | -6% | reduced |
| 30 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 1.1% | $10.3m | 1,946,482 | – | new |
| 31 | CERS CERUS CORP | Healthcare | 1.1% | $10.1m | 3,472,737 | 9% | added |
| 32 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.0% | $9.2m | 500,402 | – | new |
| 33 | BENITEC BIOPHARMA INC | 1.0% | $9.1m | 679,826 | -5% | reduced | |
| 34 | PCVX VAXCYTE INC | Healthcare | 0.9% | $8.4m | 145,000 | 0% | held |
| 35 | WGS GENEDX HOLDINGS CORP | Healthcare | 0.9% | $8.4m | 122,269 | – | new |
| 36 | SVRA SAVARA INC | Healthcare | 0.9% | $8.3m | 1,355,459 | -5% | reduced |
| 37 | OVID OVID THERAPEUTICS INC | Healthcare | 0.9% | $8.3m | 3,101,129 | 210% | added |
| 38 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.9% | $8.0m | 738,873 | -33% | reduced |
| 39 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.8% | $7.1m | 503,382 | 68% | added |
| 40 | CGEN COMPUGEN LTD | Healthcare | 0.8% | $6.8m | 3,184,257 | -4% | reduced |
| 41 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.7% | $6.7m | 668,450 | – | new |
| 42 | IBIO IBIO INC | 0.7% | $6.2m | 3,520,490 | 1458% | added | |
| 43 | IRON DISC MEDICINE INC | Healthcare | 0.7% | $6.1m | 82,800 | -58% | reduced |
| 44 | ALKS ALKERMES PLC | Healthcare | 0.7% | $5.9m | 113,494 | -75% | reduced |
| 45 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 0.6% | $5.3m | 59,959 | -68% | reduced |
| 46 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.6% | $5.1m | 525,000 | – | new | |
| 47 | CTNM CONTINEUM THERAPEUTICS INC | 0.5% | $4.9m | 296,135 | -2% | reduced | |
| 48 | UNIQURE NV | 0.5% | $4.8m | 105,000 | – | new | |
| 49 | RESEARCH ALLIANCE CORP III | 0.4% | $3.9m | 360,000 | – | new | |
| 50 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 0.4% | $3.8m | 610,407 | -6% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.